Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Website: jnj.com


  • Good financial results growth rate 248.9% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (8.1%)
  • Dividend yield for the last twelve months 3.3%
  • Free cash flow yield 0.0% (LTM)
  • Share price is 2.4% higher than minimum and 20.5% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (14.5x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: JNJ
Share price, USD:  (+1.5%)147.91
year average price 159.05  


year start price 162.69 2023-04-22

max close price 174.48 2023-07-28

min close price 144.45 2024-04-16

current price 147.91 2024-04-20
Common stocks: 2 631 399 832

Dividend Yield:  3.3%
EV / LTM EBITDA: 14.5x
EV / EBITDA annualized: 13.9x
Last revenue growth (y/y):  -13.6%
Last growth of EBITDA (y/y):  200.0%
Historical revenue growth:  2.9%
Historical growth of EBITDA:  13.2%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 389 210
Net Debt ($m): 32 590
EV (Enterprise Value): 421 800
EBITDA LTM ($m): 29 048
EV / LTM EBITDA: 14.5x
Price to Book: 5.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2024-04-20InvestorPlace

Investing for the Long-Term: 3 Stocks With Proven Track Records

2024-04-19Reuters

WHO says wider alert on contaminated J&J cough syrup 'likely'

2024-04-19Forbes

What's Next For Johnson & Johnson Stock After Beating Q1 Earnings?

2024-04-18Reuters

J&J wins trial over Florida woman who claimed its baby powder caused her cancer

2024-04-16PYMNTS

Johnson & Johnson Amplifies MedTech Profile in Q1 Earnings

2024-04-16Schwab Network

Johnson & Johnson (JNJ) Shockwave Deal & Earnings Takeaways

2024-04-16Zacks Investment Research

J&J (JNJ) Q1 Earnings Beat Estimates, Sales Miss, MedTech Soft

2024-04-16Proactive Investors

J&J's first quarter profits top estimates on strong cancer drug sales

2024-04-16Zacks Investment Research

Johnson & Johnson (JNJ) Reports Q1 Earnings: What Key Metrics Have to Say

2024-04-16Investopedia

Johnson & Johnson Stock Slips After Mixed Q1 Earnings Report
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data